We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pfizer's Leukemia Candidate Gets Priority Review in U.S.
Read MoreHide Full Article
Pfizer Inc. (PFE - Free Report) announced that its Biologics License Application (BLA) for leukemia candidate inotuzumab ozogamicin has been accepted for priority review by the FDA.
Inotuzumab ozogamicin is being evaluated for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
With the FDA granting priority review, a response should be out by Aug 2017.
Pfizer’s share price increased 3.5% year- to -date compared with the Zacks classified Large Cap Pharmaceuticals industry’s gain of 4.4%.
Inotuzumab ozogamicin received Breakthrough Therapy designation from the FDA in October 2015 for ALL. The submission was based on phase III study -INO-VATE ALL or Study 1022. The open-label, randomized study evaluated the safety and efficacy of the candidate, in comparison to investigator-choice chemotherapy, in adults (n=326) with relapsed or refractory CD22-positive ALL.
The study had two primary endpoints – complete response with or without hematologic remission and overall survival (OS). Data from the study revealed an improvement over chemotherapy on a number of measures that included complete hematologic remission and progression-free survival (PFS). The study met its first primary endpoint of complete response, but failed to reach statistical significance in its second primary endpoint.
However, the second primary endpoint of OS demonstrated a strong trend toward longer OS. A Marketing Authorization Application (MAA) for inotuzumab ozogamicin for the same indication is alreadyunder review in Europe.
Pfizer currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector include Sunesis Pharmaceuticals , Exact Sciences Corp. (EXAS - Free Report) , and GlaxoSmithKline plc (GSK - Free Report) . While Sunesis carries a Zacks Rank#1 (Strong Buy), Exact Sciences and GlaxoSmithKline carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here
Sunesis’ loss estimates narrowed by 5.06% and 8.80% for 2016 and 2017, respectively, over the past 30 days. The company recorded a positive earnings surprise in three of the last four quarters, the average being 0.54%.
GlaxoSmithKline’s earnings estimates increased from $2.64 to $2.76 for 2017 and from $2.78 to $2.85 for 2018 over the last 30 days. The company posted a positive earnings surprise in three of the four trailing quarters with an average beat of 11.03%. Its share price increased 4.4% year to date.
Exact Sciences’ loss estimates narrowed by 1.17% and 3.57% for 2016 and 2017, respectively, over the past 60 days. The company recorded a positive earnings surprise in all of the last four quarters, the average being 14.12%.
Zacks' Top Investment Ideas for Long-Term Profit
How would you like to see our best recommendations to help you find today’s most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Pfizer's Leukemia Candidate Gets Priority Review in U.S.
Pfizer Inc. (PFE - Free Report) announced that its Biologics License Application (BLA) for leukemia candidate inotuzumab ozogamicin has been accepted for priority review by the FDA.
Inotuzumab ozogamicin is being evaluated for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
With the FDA granting priority review, a response should be out by Aug 2017.
Pfizer’s share price increased 3.5% year- to -date compared with the Zacks classified Large Cap Pharmaceuticals industry’s gain of 4.4%.
Inotuzumab ozogamicin received Breakthrough Therapy designation from the FDA in October 2015 for ALL. The submission was based on phase III study -INO-VATE ALL or Study 1022. The open-label, randomized study evaluated the safety and efficacy of the candidate, in comparison to investigator-choice chemotherapy, in adults (n=326) with relapsed or refractory CD22-positive ALL.
The study had two primary endpoints – complete response with or without hematologic remission and overall survival (OS). Data from the study revealed an improvement over chemotherapy on a number of measures that included complete hematologic remission and progression-free survival (PFS). The study met its first primary endpoint of complete response, but failed to reach statistical significance in its second primary endpoint.
However, the second primary endpoint of OS demonstrated a strong trend toward longer OS. A Marketing Authorization Application (MAA) for inotuzumab ozogamicin for the same indication is alreadyunder review in Europe.
Pfizer, Inc. Price
Pfizer, Inc. Price | Pfizer, Inc. Quote
Zacks Rank & Key Picks
Pfizer currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector include Sunesis Pharmaceuticals , Exact Sciences Corp. (EXAS - Free Report) , and GlaxoSmithKline plc (GSK - Free Report) . While Sunesis carries a Zacks Rank#1 (Strong Buy), Exact Sciences and GlaxoSmithKline carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here
Sunesis’ loss estimates narrowed by 5.06% and 8.80% for 2016 and 2017, respectively, over the past 30 days. The company recorded a positive earnings surprise in three of the last four quarters, the average being 0.54%.
GlaxoSmithKline’s earnings estimates increased from $2.64 to $2.76 for 2017 and from $2.78 to $2.85 for 2018 over the last 30 days. The company posted a positive earnings surprise in three of the four trailing quarters with an average beat of 11.03%. Its share price increased 4.4% year to date.
Exact Sciences’ loss estimates narrowed by 1.17% and 3.57% for 2016 and 2017, respectively, over the past 60 days. The company recorded a positive earnings surprise in all of the last four quarters, the average being 14.12%.
Zacks' Top Investment Ideas for Long-Term Profit
How would you like to see our best recommendations to help you find today’s most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>